ArticleVeterinary and animal science2025
Network pharmacology and experimental validation of Compound Kushen Powder for the treatment of diarrhea in vivo.
Article in Veterinary and animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fraxini cortex (Qinpi): reframing a traditional heat-clearing botanical drug as a systemic immune-metabolic regulator.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the mechanism of sophora flavescens, cortex fraxini, and pomegranate peel complex powder (Compound Kushen Powder) in the treatment of animal diarrhea, a network pharmacology approach leveraging databases like TCMSP and SwissTarget was applied in this study. Molecular docking was executed between the primary constituents and pivotal targets, enabling an additional refinement of main targets and key medications. Subsequently, a rat diarrhea model induced by folium sennae leaves was established for in vivo validation. The rats were divided into four groups: negative control group, positive control group, positive drug treatment group, and Compound Kushen Powder treatment group. Key protein targets, such as Caspase-3, IL-1β, IL-10, MMP9, STAT3, TNF, TP53, and VEGFA, essential for mitigating diarrhea in response to the composite medication were found through network pharmacology. Additionally, the results of molecular docking analysis unveiled fundamental constituents of Compound Kushen Powder, namely beta-sitosterol, ursolic acid, formononetin, and matrine, which demonstrated significant binding affinities with those identified key protein targets. The results of mRNA and protein expression analyses of rat colonic tissue validated the in vivo alterations of core genes identified through network screening. Except for IL-10 and STAT3, the expression of all targets exhibited noteworthy reductions when compared to the positive control group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.